Send to

Choose Destination
Clin Pharmacol Drug Dev. 2014 Jul;3(4):262-9. doi: 10.1002/cpdd.102. Epub 2014 Feb 9.

A double-blind, randomized, ascending, multiple-dose study of bazedoxifene in healthy postmenopausal women.

Author information

Pfizer Inc, Collegeville, PA, USA.
No longer affiliated with Pfizer Inc, USA.
Teva Pharmaceuticals, North Wales, PA, USA.
Shire Pharmaceuticals, Wayne, PA, USA.
Amgen Inc, Thousand Oaks, CA, USA.


Bazedoxifene is a novel selective estrogen receptor modulator in clinical development for the prevention and treatment of postmenopausal osteoporosis. This phase 1, double-blind, randomized, placebo-controlled study (N = 107) of healthy postmenopausal women examined the pharmacokinetics and safety/tolerability profile of multiple doses of bazedoxifene (1, 2.5, 5, 10, 20, 40, and 80 mg) administered orally once daily for 30 days. Bazedoxifene demonstrated a half-life of 25 to 30 hours, reached steady state within 7 days, and exhibited linear pharmacokinetics over a dose range of 5-80 mg. Fibrinogen levels decreased with bazedoxifene doses of 5 mg and greater; these changes were significant for bazedoxifene 20, 40, and 80 mg (P ≤ .05 vs placebo), but were not dose dependent. Bazedoxifene was associated with increased levels of sex hormone-binding globulin, thyroxine-binding globulin, and cortisol-binding globulin (CBG); only increases in the levels of CBG appeared to be dose related. Bazedoxifene was safe and well tolerated within the tested dose range. Bazedoxifene showed no differences from placebo in adverse event reports, vital sign measurements, or electrocardiogram findings.


bazedoxifene; menopause; osteoporosis; pharmacokinetics; selective estrogen receptor modulator

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center